Brief: Adhera Therapeutics Says Melior Pharmaceuticals II Terminates License Deal With Respect To MLR-1019
18/01/2024 23:07
Jan 18 (Reuters) - Adhera Therapeutics Inc ATRX.PK :
* ADHERA THERAPEUTICS: MELIOR PHARMACEUTICALS II TERMINATES
LICENSE DEAL WITH RESPECT TO MLR-1019, A NEW CLASS OF
THERAPEUTIC FOR PARKINSON'S DISEASE
* ADHERA THERAPEUTICS: ACCORDING TO MELIOR'S TERMINATION
NOTICE,
MELIOR DETERMINED, ADHERA FAILED TO CONTINUE COMMERCIALLY
REASONABLE EFFORTS
Further company coverage: ATRX.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Adhera Therapeutics
See all newsBrief: Adhera Therapeutics Says Melior Pharmaceuticals II Terminates License Deal With Respect To MLR-1019
Brief: Adhera Therapeutics Announces CEO, Senior Management Changes, Plans For Nasdaq Uplist
Brief: Adhera Therapeutics Signs Letter Of Intent With Melior Pharmaceuticals Ii To Acquire A New Class Of Drug For Parkinson’S Disease
Ontario to begin offering second doses of COVID-19 vaccines
Brief: Adhera Therapeutics Inc Determined That Co Would Terminate Its Current Business Operations